• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4661586)   Today's Articles (52)   Subscriber (51518)
For: Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol 2023;24:443-451. [PMID: 36855020 PMCID: PMC9974384 DOI: 10.1007/s40257-023-00764-w] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/20/2023] [Indexed: 03/02/2023]
Number Cited by Other Article(s)
1
Kalil L, King B. Innovation in Alopecia Areata. Dermatol Clin 2025;43:27-33. [PMID: 39542562 DOI: 10.1016/j.det.2024.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2024]
2
Dall'Oglio F, Nasca MR, Lacarrubba F, Vitale P, Micali G. Alopecia areata treatment with baricitinib: different relapse phenotypes. J DERMATOL TREAT 2024;35:2324832. [PMID: 38465657 DOI: 10.1080/09546634.2024.2324832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Accepted: 02/23/2024] [Indexed: 03/12/2024]
3
De la Torre-Gomar FJ, Velasco-Amador JP, Prados-Carmona Á, Ruiz-Villaverde R. Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib. J DERMATOL TREAT 2024;35:2304630. [PMID: 38240097 DOI: 10.1080/09546634.2024.2304630] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 01/02/2024] [Indexed: 01/23/2024]
4
Mostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, Brogan Y, King B. Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year. J Eur Acad Dermatol Venereol 2024. [PMID: 39569884 DOI: 10.1111/jdv.20334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Accepted: 09/03/2024] [Indexed: 11/22/2024]
5
Guo HW, Ye ZM, Chen SQ, McElwee KJ. Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system. Expert Opin Drug Discov 2024;19:1321-1338. [PMID: 39360759 DOI: 10.1080/17460441.2024.2409660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2024] [Accepted: 09/24/2024] [Indexed: 10/05/2024]
6
Zhang X, Jiang Y. Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata. Am J Clin Dermatol 2024;25:975-986. [PMID: 39225949 DOI: 10.1007/s40257-024-00884-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2024] [Indexed: 09/04/2024]
7
Perricone C, Dal Pozzolo R, Cafaro G, Calvacchi S, Bruno L, Tromby F, Colangelo A, Gerli R, Bartoloni E. Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review. Reumatismo 2024. [PMID: 39470166 DOI: 10.4081/reumatismo.2024.1685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 06/06/2024] [Indexed: 10/30/2024]  Open
8
Gates E, Takwale A, Jamal MS. From joint pains to hair gains: baricitinib's double duty for rheumatoid arthritis and alopecia areata. BMJ Case Rep 2024;17:e260021. [PMID: 39455076 DOI: 10.1136/bcr-2024-260021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2024]  Open
9
King B, Ko J, Kwon O, Vañó-Galván S, Piraccini BM, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska NA. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatol 2024;160:1075-1081. [PMID: 39141364 PMCID: PMC11325239 DOI: 10.1001/jamadermatol.2024.2734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Accepted: 06/13/2024] [Indexed: 08/15/2024]
10
Caldarola G, Raimondi G, Samela T, Pinto L, Pampaloni F, Starace MVR, Diluvio L, Dall'Oglio F, Vagnozzi E, de Felici del Giudice MB, Balestri R, Ambrogio F, Girolomoni G, Riva SF, Moro F, Atzori L, Gallo G, Ribero S, Simonetti O, Barruscotti S, Boccaletti V, Marzano AV, Bianchi L, Micali G, Piraccini BM, Fargnoli MC, Abeni D, Peris K. Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study. Front Public Health 2024;12:1415334. [PMID: 39220459 PMCID: PMC11363427 DOI: 10.3389/fpubh.2024.1415334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Accepted: 07/18/2024] [Indexed: 09/04/2024]  Open
11
Tang GT, Triwongwaranat D, Sinclair R, Joseph S, Eisman S, Rathnayake D, Varathan V, Trindade de Carvalho L, Bhoyrul B. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib. Clin Exp Dermatol 2024;49:875-878. [PMID: 38270233 DOI: 10.1093/ced/llae033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 12/07/2023] [Accepted: 01/15/2024] [Indexed: 01/26/2024]
12
Song CJ, Riley CA, Wilkison BD, Cho S. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System. Mil Med 2024:usae292. [PMID: 38850223 DOI: 10.1093/milmed/usae292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 04/23/2024] [Accepted: 05/22/2024] [Indexed: 06/10/2024]  Open
13
Mostaghimi A, Ko J, Tosti A, McMichael A, Ohyama M, Ito T, Dutronc Y, Ball S, Yu G, Murage M, Chen YF, Chiasserini C, Wollenberg A. Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies. J Am Acad Dermatol 2024:S0190-9622(24)00846-6. [PMID: 38852742 DOI: 10.1016/j.jaad.2024.05.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 04/29/2024] [Accepted: 05/21/2024] [Indexed: 06/11/2024]
14
Ahmed F, Rahman SM, Trent S, Haque A. The development of oral hairy leukoplakia during baricitinib therapy. JAAD Case Rep 2024;48:141-143. [PMID: 38868159 PMCID: PMC11167197 DOI: 10.1016/j.jdcr.2023.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2024]  Open
15
Desai DD, Nohria A, Lo Sicco KI, Shapiro J. Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure. Cureus 2024;16:e63120. [PMID: 39055467 PMCID: PMC11271686 DOI: 10.7759/cureus.63120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/25/2024] [Indexed: 07/27/2024]  Open
16
Chim I, Ghiya R, Sinclair RD, Eisman S. Novel investigational drugs for alopecia areata and future perspectives. Expert Opin Investig Drugs 2024;33:441-449. [PMID: 38682280 DOI: 10.1080/13543784.2024.2348062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Accepted: 04/22/2024] [Indexed: 05/01/2024]
17
von Martial S, Tsianakas A. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?]. DERMATOLOGIE (HEIDELBERG, GERMANY) 2024;75:256-267. [PMID: 38100043 DOI: 10.1007/s00105-023-05253-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 10/18/2023] [Indexed: 02/21/2024]
18
Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci 2024;113:86-92. [PMID: 38326166 DOI: 10.1016/j.jdermsci.2023.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 12/28/2023] [Indexed: 02/09/2024]
19
Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol 2024;38:583-593. [PMID: 38391212 DOI: 10.1111/jdv.19665] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 10/20/2023] [Indexed: 02/24/2024]
20
Katamanin O, Ch’en PY, Song EJ. Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy. JAAD Case Rep 2024;43:36-39. [PMID: 38125968 PMCID: PMC10731593 DOI: 10.1016/j.jdcr.2023.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]  Open
21
Panda AK, Ranjan S, Sahu JK. Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials. Int J Rheum Dis 2024;27:e14964. [PMID: 37950554 DOI: 10.1111/1756-185x.14964] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 09/10/2023] [Accepted: 10/27/2023] [Indexed: 11/12/2023]
22
Bi L, Wang C, Du Y, Su T, Zhao M, Lin X, Fan W, Sun W. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study. J Cosmet Dermatol 2023. [PMID: 38116864 DOI: 10.1111/jocd.16123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/10/2023] [Accepted: 11/28/2023] [Indexed: 12/21/2023]
23
Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb) 2023;13:3209-3220. [PMID: 37991697 PMCID: PMC10689319 DOI: 10.1007/s13555-023-01063-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Accepted: 10/25/2023] [Indexed: 11/23/2023]  Open
24
Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, Marzano AV, Barbareschi M, Bianchi VG, Valenti M, Costanzo A, Narcisi A. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J DERMATOL TREAT 2023;34:2268764. [PMID: 37818648 DOI: 10.1080/09546634.2023.2268764] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 10/04/2023] [Indexed: 10/12/2023]
25
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, Sinclair R, Chen YF, Wu WS, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol 2023;189:666-673. [PMID: 37708254 DOI: 10.1093/bjd/ljad253] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 07/13/2023] [Indexed: 09/16/2023]
26
Tachet J, Versace F, Mercier T, Buclin T, Decosterd LA, Choong E, Girardin FR. Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2023;1230:123917. [PMID: 37956468 DOI: 10.1016/j.jchromb.2023.123917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 10/25/2023] [Accepted: 10/27/2023] [Indexed: 11/15/2023]
27
Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin DJ, Randhawa S, Winkler A, Telliez JB, Martin D, Lejeune A. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol 2023;14:1243556. [PMID: 38022501 PMCID: PMC10657858 DOI: 10.3389/fimmu.2023.1243556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 10/05/2023] [Indexed: 12/01/2023]  Open
28
De Greef A, Thirion R, Ghislain PD, Baeck M. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data. Dermatol Ther (Heidelb) 2023;13:2869-2877. [PMID: 37717224 PMCID: PMC10613164 DOI: 10.1007/s13555-023-01030-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 09/05/2023] [Indexed: 09/19/2023]  Open
29
Uchida H, Kamata M, Watanabe A, Ito M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis. J Dermatol 2023;50:e392-e393. [PMID: 37485732 DOI: 10.1111/1346-8138.16893] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 06/15/2023] [Accepted: 06/23/2023] [Indexed: 07/25/2023]
30
Hébert V, Joly P. Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series. Clin Exp Dermatol 2023;48:1258-1259. [PMID: 37467740 DOI: 10.1093/ced/llad239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Indexed: 07/21/2023]
31
Toh EQ, Wang ECE. Targeted immunotherapy for hair regrowth and regeneration. Front Med (Lausanne) 2023;10:1285452. [PMID: 37881630 PMCID: PMC10595013 DOI: 10.3389/fmed.2023.1285452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 09/26/2023] [Indexed: 10/27/2023]  Open
32
Faria S, Freitas E, Torres T. Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date. Drugs Context 2023;12:2023-6-2. [PMID: 37781168 PMCID: PMC10537548 DOI: 10.7573/dic.2023-6-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2023] [Accepted: 08/25/2023] [Indexed: 10/03/2023]  Open
33
Gupta AK, Wang T, Bamimore MA, Piguet V, Tosti A. The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials. J Cosmet Dermatol 2023;22:2553-2559. [PMID: 37452455 DOI: 10.1111/jocd.15903] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 06/20/2023] [Accepted: 06/21/2023] [Indexed: 07/18/2023]
34
Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol 2023;159:970-976. [PMID: 37556146 PMCID: PMC10413213 DOI: 10.1001/jamadermatol.2023.2581] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Accepted: 06/13/2023] [Indexed: 08/10/2023]
35
Fung S, Shirley M. Baricitinib: A Review in Severe Alopecia Areata. Am J Clin Dermatol 2023:10.1007/s40257-023-00799-z. [PMID: 37326792 DOI: 10.1007/s40257-023-00799-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2023] [Indexed: 06/17/2023]
36
Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs 2023:10.1007/s40265-023-01873-w. [PMID: 37195491 DOI: 10.1007/s40265-023-01873-w] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2023] [Indexed: 05/18/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA